Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib.

Ivo N SahBandar, Chandler B Sy,Tayler van den Akker,David Kim,Julia T Geyer,Amy Chadburn,Ethel Cesarman,Giorgio Inghirami,John Allan,Momin T Siddiqui,Madhu M Ouseph

Pathobiology : journal of immunopathology, molecular and cellular biology（2023）

Cited 0|Views22

No score

Abstract

We hypothesize that the loss of T-cell function secondary to TKI therapy (dasatinib) may have resulted in the unchecked cellular proliferation of KSHV-infected cells, leading to the emergence of a PEL. We recommend cytologic investigation and KSHV testing in patients being treated with dasatinib for CML who present with persistent or recurrent effusions.

Translated text

Key words

lymphoma,chronic myeloid leukemia,hiv-negative

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined